Inside informationEnglish
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 22/04/2026, 23:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 117421_20260422